Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.

EMBO Molecular Medicine
Emma J SearleTim M Illidge

Abstract

Radiotherapy is an important anti-cancer treatment, but tumour recurrence remains a significant clinical problem. In an effort to improve outcomes further, targeted anti-cancer drugs are being tested in combination with radiotherapy. Here, we have studied the effects of Akt inhibition with AZD5363. AZD5363 administered as an adjuvant after radiotherapy to FaDu and PE/CA PJ34 tumours leads to long-term tumour control, which appears to be secondary to effects on the irradiated tumour microenvironment. AZD5363 reduces the downstream effectors VEGF and HIF-1α, but has no effect on tumour vascularity or oxygenation, or on tumour control, when administered prior to radiotherapy. In contrast, AZD5363 given after radiotherapy is associated with marked reductions in tumour vascular density, a decrease in the influx of CD11b+ myeloid cells and a failure of tumour regrowth. In addition, AZD5363 is shown to inhibit the proportion of proliferating tumour vascular endothelial cells in vivo, which may contribute to improved tumour control with adjuvant treatment. These new insights provide promise to improve outcomes with the addition of AZD5363 as an adjuvant therapy following radiotherapy.

References

Jun 1, 2002·Science·Lewis C Cantley
Sep 18, 2003·Nature Reviews. Cancer·Gregg L Semenza
Sep 3, 2004·Nature Reviews. Cancer·Jacques BernierAmato Giaccia
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kaye J WilliamsStephen R Wedge
Jun 21, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Shubha VarmaWalter N Durán
Jul 5, 2006·Molecular Cancer Therapeutics·Lorena de la PeñaPhilip J Tofilon
May 1, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Olga C J SchuurbiersJohan Bussink
Jul 15, 2009·Advances in Cancer Research·Bing-Hua Jiang, Ling-Zhi Liu
May 27, 2010·British Journal of Cancer·P WorkmanUNKNOWN Committee of the National Cancer Research Institute
Oct 6, 2011·Molecular Cancer Therapeutics·Joana M SenraIan J Stratford
Nov 24, 2011·PloS One·Enrique ZudaireSonja Vermeren
May 11, 2012·Journal of the National Cancer Institute·Sergey V KozinRakesh K Jain
Jul 25, 2013·Frontiers in Physiology·Jeffery S Russell, J Martin Brown
Jun 25, 2015·Nature Reviews. Cancer·Holly E BarkerKevin J Harrington
Feb 11, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Esme J HillRicky A Sharma
Apr 1, 2015·Molecular & Cellular Oncology·Adriana SolerMariona Graupera

❮ Previous
Next ❯

Citations

Feb 12, 2019·Cell Cycle·Man-Hei CheungChun Liang
Jun 5, 2019·PLoS Computational Biology·Tamara C BidoneGregory A Voth
Jan 11, 2020·Journal of Experimental & Clinical Cancer Research : CR·Pan WangJie He
May 20, 2018·CNS Neuroscience & Therapeutics·Xiao YangWei-Liang Xia
Oct 9, 2020·Signal Transduction and Targeted Therapy·Siyuan QinWeifeng He
Mar 7, 2021·International Journal of Molecular Sciences·Mariam MrowehZuzana Macek Jílková

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
xenograft
xenografts
biopsy
PCR

Software Mentioned

InVivostat
GraphPad Prism
GraphPad
Tissue Studio
AngioTool
Photoshop Express
Summit

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.